TY - JOUR
T1 - The power of youth
T2 - Long-term differential effects of developmental functioning trajectory on social functioning, quality of life and personal recovery across the schizophrenia spectrum
AU - Hao, Jiasi
AU - Alizadeh, Behrooz Z.
AU - van Amelsvoort, Therese
AU - Cahn, Wiepke
AU - de Haan, Lieuwe
AU - van der Pluijm, Marieke
AU - Simons, Claudia J.P.
AU - van Os, Jim
AU - Veling, Wim
AU - Bruggeman, Richard
AU - Alizadeh, Behrooz Z.
AU - Genetic Risk and Outcome of Psychosis (GROUP) Investigators
N1 - Funding Information:
This work was supported by Geestkracht programme of the Dutch Health Research Council (Zon-Mw) (10\u2212000\u22121001), and matching funds from participating pharmaceutical companies (Lundbeck; AstraZeneca; Eli Lilly and Janssen Cilag) and Universities and Mental Health Care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Centre and the mental health institutions: GGZ Ingeest; Arkin, Dijk en Duin; GGZ Rivierduinen; Erasmus Medical Centre and GGZ Noord Holland Noord. Groningen: University Medical Centre Groningen and the mental health institutions: Lentis, GGZ Friesland; GGZ Drenthe; Dimence; Mediant; GGNet Warnsveld; Yulius Dordrecht and Parnassia psycho-medical centre The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGZ Eindhoven en De Kempen; GGZ Breburg; GGZ Oost-Brabant; Vincent van Gogh voor Geestelijke Gezondheid; Mondriaan; Virenze riagg; Zuyderland GGZ; MET ggz; Universitair Centrum Sint-Jozef Kortenberg; CAPRI University of Antwerp; PC Ziekeren Sint-Truiden; PZ Sancta Maria Sint-Truiden; GGZ Overpelt and OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions: Altrecht; GGZ Centraal and Delta). The sponsors have no role in designing the study, in the collection, analysis, and interpretation of data, in the writing of the report and in the decision to submit the paper for publication.
Publisher Copyright:
© 2025 The Authors
PY - 2025/11/1
Y1 - 2025/11/1
N2 - Background: Compromised developmental functioning is frequently observed in patients with schizophrenia spectrum disorder (SSD) and is associated with poor outcomes, which remains understudied in individuals at varying risk of SSD. This study aimed to investigate the course of developmental functioning and its relationship with long-term outcomes within a population across the vulnerability spectrum of SSD. We hypothesized that developmental functioning negatively correlated with SSD vulnerability, and was positively associated with worse outcomes, regardless of disease status. Methods: We used data of 1119 patients, 1059 siblings, and 586 controls from the Dutch Genetic Risk and Outcome in Psychosis (GROUP) cohort. Group-based trajectory modelling and linear mixed models were employed to investigate the course of developmental functioning (measured by the Premorbid Adjustment Scale) and its associations with the outcomes, including social functioning (SF), personal recovery (PR), and quality of life (QoL). Results: In the combined sample, six developmental trajectories were identified: normal-stable (12.4 %), normal-slow decrease (12.3 %), mild-stable (46.9 %), all dominated by controls and siblings; and mild-rapid decrease (5.1 %), moderate-stable (16.5 %), and severe-slow decrease (6.8 %) more prevalent in patients. Compared to normal-stable, all other trajectories in developmental functioning were correlated with decreased SF; mild-rapid decrease and severe-slow decrease were linked to lower QoL. No association with PR was observed. Conclusion: Impaired developmental functioning variably lowers prolonged SF and QoL but not PR. Potentially influenced by factors encompassing environment, cognition, resilience and disease status, this finding demands screening for developmental deviance among youths and early preventive interventions to achieve normal functioning through a public health salutogenic approach.
AB - Background: Compromised developmental functioning is frequently observed in patients with schizophrenia spectrum disorder (SSD) and is associated with poor outcomes, which remains understudied in individuals at varying risk of SSD. This study aimed to investigate the course of developmental functioning and its relationship with long-term outcomes within a population across the vulnerability spectrum of SSD. We hypothesized that developmental functioning negatively correlated with SSD vulnerability, and was positively associated with worse outcomes, regardless of disease status. Methods: We used data of 1119 patients, 1059 siblings, and 586 controls from the Dutch Genetic Risk and Outcome in Psychosis (GROUP) cohort. Group-based trajectory modelling and linear mixed models were employed to investigate the course of developmental functioning (measured by the Premorbid Adjustment Scale) and its associations with the outcomes, including social functioning (SF), personal recovery (PR), and quality of life (QoL). Results: In the combined sample, six developmental trajectories were identified: normal-stable (12.4 %), normal-slow decrease (12.3 %), mild-stable (46.9 %), all dominated by controls and siblings; and mild-rapid decrease (5.1 %), moderate-stable (16.5 %), and severe-slow decrease (6.8 %) more prevalent in patients. Compared to normal-stable, all other trajectories in developmental functioning were correlated with decreased SF; mild-rapid decrease and severe-slow decrease were linked to lower QoL. No association with PR was observed. Conclusion: Impaired developmental functioning variably lowers prolonged SF and QoL but not PR. Potentially influenced by factors encompassing environment, cognition, resilience and disease status, this finding demands screening for developmental deviance among youths and early preventive interventions to achieve normal functioning through a public health salutogenic approach.
KW - Development
KW - Functioning
KW - Premorbid
KW - Prevention
KW - Psychosis
KW - Public Health
U2 - 10.1016/j.comppsych.2025.152637
DO - 10.1016/j.comppsych.2025.152637
M3 - Article
SN - 0010-440X
VL - 143
JO - Comprehensive Psychiatry
JF - Comprehensive Psychiatry
M1 - 152637
ER -